Mount Sinai Surgeons Perform First Human Tracheal Transplant Surgery
Historic case launches Mount Sinai’s Tracheal Transplant Program for treating patients worldwide, including those with severe intubation damage after COVID-19
A team of Mount Sinai surgeons has performed the world’s first human tracheal transplant—an achievement that has the potential to save the lives of thousands of patients around the world who have tracheal birth defects, untreatable airway diseases, burns, tumors, or severe tracheal damage from intubation, including those who had been hospitalized with COVID-19 and placed on a ventilator. Until now, no long-term treatments existed for these patients with long-segment tracheal damage, and thousands of adults and children died each year as a result.
The trachea, also known as the windpipe, is an organ that is essential for speaking, breathing, and normal lung function. The trachea connects the larynx to the lungs and plays a critical role in normal lung function, the immune system, and breathing.
Surgeons have been unable to transplant this organ in large part because of the complexity of providing blood flow to the donor trachea, leaving patients with long-segment tracheal disease no option for treatment. Mount Sinai’s historic procedure resulted from 30 years of research, much of it focused on how to revascularize, or provide blood flow to the trachea.
The 18-hour procedure took place on Wednesday, January 13, and was led by surgeon-scientist Eric M. Genden, MD, MHCA, FACS, the Isidore Friesner Professor and Chair of Otolaryngology – Head and Neck Surgery for Mount Sinai Health System and Professor of Neurosurgery, and Immunology, at the Icahn School of Medicine at Mount Sinai. The complex surgery involved a team of more than 50 specialists including surgeons, nurses, anesthesiologists, and residents.
“For the first time, we are able to offer a viable treatment option to patients with life-compromising long-segment tracheal defects, and this development will change the standard of care. It is particularly timely given the growing number of patients with extensive tracheal issues due to COVID-19 intubation. Because of both mechanical ventilation and the nature of the COVID-19-induced airway disease, tracheal airway disease is precipitously increasing, and now we have a treatment. Our trachea transplantation and revascularization protocol is reliable, reproducible, and technically straightforward,” says Dr. Genden. “For years, the medical and scientific consensus has been that trachea transplantation could not be done because the organ’s complexity made revascularization impossible, and every previous attempt to perform in-human transplantation ended in failure. This surgical achievement is not only the culmination of 30 years of research that began when I was a medical student at Mount Sinai, but was also made possible by the spirit of collaboration that exists at Mount Sinai.”
The trachea transplant recipient is a 56-year-old female social worker from New York City. She had severe tracheal damage due to repeated intubation after an asthma attack; several failed surgical attempts to reconstruct her trachea led to even further damage. She breathed through a tracheostomy—a surgically created hole in her neck—and was at high risk of suffocation and death because of the progression of her airway disease and likelihood of her trachea collapsing. Being constantly worried she would go to sleep at night and never wake up was her main motivator to undergo the experimental procedure.
During the procedure, the Mount Sinai surgical team removed the trachea and the associated blood vessels from the donor. Then, the surgeons reconstructed the trachea in the recipient from the lungs to the larynx and performed a series of microvascular anastomoses, connecting the small blood vessels that nourish the donor trachea with the recipient’s blood vessels. Surgeons used a portion of the esophagus and thyroid gland to help provide blood supply to the trachea, which led to successful revascularization. Ultimately, this procedure allowed the removal of the recipient’s tracheostomy, giving her an opportunity to breathe through her mouth for the first time in six years.
“Despite extensive research on the vascular supply to the organ using human and animal models, there is no real way to fully prepare for conducting a first-ever in-human transplantation such as this,” Dr. Genden said. “For example, we had no guide for how well the graft would tolerate transplantation, so we worked very quickly. Eighteen hours later, it was clear we had accomplished what many said could not be done. Ultimately, everything went smoothly because we assembled a strong team with extensive surgical expertise in organ transplantation and tracheal reconstruction. Seeing the graft come alive and knowing that the organ was well vascularized was an amazing experience. Knowing that this procedure and 30 years of research will save countless lives was indescribable. It is why we do what we do, to make a difference.”
The patient has had no complications or signs of organ rejection and doctors are monitoring her closely to assess her progress and reaction to antirejection therapy. Their observations will inform the development of Mount Sinai’s Tracheal Transplant Program, enabling Dr. Genden to offer this therapeutic approach to patients nationwide and internationally.
“Mount Sinai has had many firsts and this extraordinary effort was the result of Dr. Genden’s vision, skills, and perseverance—as well as the strength and trust of this incredible patient,” said Sander S. Florman, MD, The Charles Miller, MD Professor of Surgery and Director of the Recanati/Miller Transplantation Institute at Mount Sinai. “The Transplant Institute is proud to support Dr. Genden’s efforts and to have the experience to help make this a new possibility for these patients.”
“From the beginning, Mount Sinai has demonstrated excellence and innovation in patient care, and the work of Dr. Genden and the surgeons who made this transplantation both possible and successful builds on that legacy,” says Kenneth L. Davis, MD, President and Chief Executive Officer of Mount Sinai Health System. “Through ongoing collaboration and research, we will continue to advance our understanding of complex medical challenges and pioneer therapeutic approaches that enable us to deliver on our mission to realize the best possible outcomes for our patients and strengthen the health of our community.”
“I applaud the entire Mount Sinai team for pioneering the first successful tracheal transplant. This historic procedure shows that organ and tissue donation is an evolving field that continues to heal and save lives in new and meaningful ways. It is important to remember that this procedure would not have been possible without the selfless organ donor who chose to give the gift of life. If you have not done so, please consider signing up as an organ, eye, and tissue donor. You too can save a life,” explains Helen Irving, President and Chief Executive Officer of LiveOnNY, the organ procurement organization that Mount Sinai worked with to receive the trachea donor.
Click on the link below to learn more about Mount Sinai’s Tracheal Transplant Program:
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report's Best Hospitals, receiving high "Honor Roll" status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children's Hospital among the country’s best in several pediatric specialties. The Icahn School of Medicine at Mount Sinai is one of three medical schools that have earned distinction by multiple indicators: It is consistently ranked in the top 20 by U.S. News & World Report's "Best Medical Schools," aligned with a U.S. News & World Report "Honor Roll" Hospital, and top 20 in the nation for National Institutes of Health funding and top 5 in the nation for numerous basic and clinical research areas. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally.